Immatics starts late-stage cancer vaccine study

Germany's Immatics Biotechnologies says its vaccinated the first first patients in a Phase III study IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.